Carl E. Ruby

2.1k citations

33 papers · 1.7k indexed · h-index 22

Impact in

Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune Response and Inflammation
Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in ⓘ

Immunology 22
- Immunotherapy and Immune Responses 16
- Immune Cell Function and Interaction 13
- T-cell and B-cell Immunology 11
- Immune Response and Inflammation 5
Biological Psychiatry 1

Co-authors: Andrew D. Weinberg (13 shared papers)William L. Redmond (4 shared papers)Howard L. Kaufman (10 shared papers)Tasha M. Hughes (3 shared papers)Craig L. Slingluff (1 shared paper)Nancy I. Kerkvliet (3 shared papers)Michael J. Gough (2 shared papers)Birat Dhungel (1 shared paper)
Journals: The Journal of Immunology (5 papers)Journal for ImmunoTherapy of Cancer (3 papers)Cancer Immunology Immunotherapy (2 papers)Journal of Medical Microbiology (2 papers)European Journal of Immunology (2 papers)
Partner nations: United States Slovakia Netherlands

In The Last Decade

Carl E. Ruby

33 papers receiving 1.6k citations

Peers

Countries citing papers authored by Carl E. Ruby

Since Specialization

Citations

This map shows the geographic impact of Carl E. Ruby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl E. Ruby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl E. Ruby more than expected).

Fields of papers citing papers by Carl E. Ruby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl E. Ruby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl E. Ruby. The network helps show where Carl E. Ruby may publish in the future.

Co-authors

The 25 scholars most cited alongside Carl E. Ruby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carl E. Ruby Line = papers co-authored together Carl E. Ruby links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma Journal for ImmunoTherapy of Cancer ·Howard L. Kaufman, Carl E. Ruby, Tasha M. Hughes, Craig L. Slingluff	2014	164
2	The Role of OX40-Mediated Co-stimulation in T-Cell Activation and Survival Critical Reviews in Immunology ·William L. Redmond, Carl E. Ruby, Andrew D. Weinberg	2009	151
3	OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor Cancer Research ·Michael J. Gough, Carl E. Ruby, William L. Redmond, Birat Dhungel, Alexis Brown, Andrew D. Weinberg	2008	139
4	Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right The Journal of Immunology ·Carl E. Ruby, Melissa A. Yates, Daniel Hirschhorn-Cymerman, Peter J. Chlebeck, Jedd D. Wolchok, Alan N. Houghton, Halina Offner, Andrew D. Weinberg	2009	126
5	Signaling Through OX40 Enhances Antitumor Immunity Seminars in Oncology ·Shawn M. Jensen, Levi D. Maston, Michael J. Gough, Carl E. Ruby, William L. Redmond, Marka R. Crittenden, Yuhuan Li, Sachin Puri, Christian Poehlein, Nick Morris, Magdalena Kovacsovics‐Bankowski, Tarsem Moudgil, Chris Twitty, Edwin Walker, Hong‐Ming Hu, Walter J. Urba, Andrew D. Weinberg, Brendan D. Curti, Bernard A. Fox	2010	109
6	Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions American Journal of Clinical Dermatology ·Marta Batus, Salman Waheed, Carl E. Ruby, Lindsay F. Petersen, Steven D. Bines, Howard L. Kaufman	2013	91
7	HIV-1 Nef Assembles a Src Family Kinase-ZAP-70/Syk-PI3K Cascade to Downregulate Cell-Surface MHC-I Cell Host & Microbe ·Chien‐Hui Hung, Laurel Thomas, Carl E. Ruby, Katelyn M. Atkins, Nicholas P. Morris, Zachary A. Knight, Isabel Scholz, Eric Barklis, Andrew D. Weinberg, Kevan M. Shokat, Gary Thomas	2007	85
8	IL-18 Bridges Innate and Adaptive Immunity through IFN-γ and the CD134 Pathway The Journal of Immunology ·Joseph R. Maxwell, Rajwardhan Yadav, Robert J. Rossi, Carl E. Ruby, Andrew D. Weinberg, Héctor L. Aguila, Anthony T. Vella	2006	82
9	Anti‐OX40 stimulation in vivo enhances CD8⁺ memory T cell survival and significantly increases recall responses European Journal of Immunology ·Carl E. Ruby, William L. Redmond, Daniel Haley, Andrew D. Weinberg	2006	77
10	Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells Experimental Cell Research ·Ryan M. Troyer, Carl E. Ruby, Cheri P. Goodall, Liping Yang, Claudia S. Maier, Hassan A. Albarqi, Jacqueline V. Brady, Kallan Bathke, Oleh Taratula, Dan V. Mourich, Shay Bracha	2017	64
11	IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival The Journal of Immunology ·Carl E. Ruby, Ryan Montler, Rongxui Zheng, Suyu Shu, Andrew D. Weinberg	2008	58
12	2,3,7,8-Tetrachlorodibenzo-p-dioxin Suppresses Tumor Necrosis Factor-α and Anti-CD40–Induced Activation of NF-κB/Rel in Dendritic Cells: p50 Homodimer Activation Is Not Affected Molecular Pharmacology ·Carl E. Ruby, Mark Leid, Nancy I. Kerkvliet	2002	55
13	Oncolytic virus therapy for cancer PubMed ·Howard L. Kaufman, Joe Goldufsky, Sivendran, Sara Harcharik, Michael Pan, Sebastian Bernardo, Richard H. Stern, Philip Friedlander, Carl E. Ruby, Yvonne M. Saenger	2013	52
14	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade Journal for ImmunoTherapy of Cancer ·Frederick J. Kohlhapp, Joseph R. Broucek, Tasha M. Hughes, Erica Huelsmann, Jevgenijs Lusciks, Janet Zayas, Hubert Dolubizno, Vidyaratna A. Fleetwood, Alisa Grin, Graham E Hill, Joseph L Poshepny, Arman Nabatiyan, Carl E. Ruby, Joshua D. Snook, Jai S. Rudra, Jason M. Schenkel, David Masopust, Andrew Zloza, Howard L. Kaufman	2015	45
15	A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease Translational Oncology ·Jacqueline V. Brady, Ryan M. Troyer, Stephen A. Ramsey, Haley Leeper, Liping Yang, Claudia S. Maier, Cheri P. Goodall, Carl E. Ruby, Hassan A. Albarqi, Oleh Taratula, Shay Bracha	2018	41
16	OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age The Journal of Immunology ·Carl E. Ruby, Andrew D. Weinberg	2009	35
17	Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines Journal of Medical Microbiology ·Joe Goldufsky, Stephen Wood, Behnam Hajihossainlou, Tooba Rehman, Omar Majdobeh, Howard L. Kaufman, Carl E. Ruby, Sasha H. Shafikhani	2015	34
18	Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity The Journal of Immunology ·Joseph R. Maxwell, Carl E. Ruby, Nancy I. Kerkvliet, Anthony T. Vella	2002	33
19	Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging Cancer Immunology Immunotherapy ·Michelle Farazi, Justine Nguyen, Josef W. Goldufsky, Stephanie Linnane, Lisa Lukaesko, Andrew D. Weinberg, Carl E. Ruby	2014	31
20	Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines Journal of Medical Microbiology ·Joe Goldufsky, Stephen Wood, Behnam Hajihossainlou, Tooba Rehman, Omar Majdobeh, Howard L. Kaufman, Carl E. Ruby, Sasha H. Shafikhani	2015	29

About Carl E. Ruby

Carl E. Ruby is a scholar working on Immunology, Biological Psychiatry, Microbiology, Cancer Research and Oncology, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (16 papers), Immune Cell Function and Interaction (13 papers), T-cell and B-cell Immunology (11 papers), CAR-T cell therapy research (5 papers), Immune Response and Inflammation (5 papers), Cancer Immunotherapy and Biomarkers (3 papers), Extracellular vesicles in disease (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Immunology (1.0k citations), Oncology (685 citations), Virology (73 citations), Cancer Research (146 citations) and Biotechnology (80 citations). Carl E. Ruby has collaborated with scholars based in United States, Slovakia and Netherlands. Frequent co-authors include Andrew D. Weinberg, William L. Redmond, Howard L. Kaufman, Tasha M. Hughes, Craig L. Slingluff, Nancy I. Kerkvliet, Michael J. Gough, Birat Dhungel, Joseph R. Maxwell and Anthony T. Vella. Their work appears in journals such as The Journal of Immunology, Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Journal of Medical Microbiology and European Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact